Investment analysts at Royal Bank Of Canada assumed coverage on shares of Celgene Corporation (NASDAQ:CELG) in a note issued to investors on Thursday, The Fly reports. The brokerage set a “top pick” rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently commented on the stock. Bank of America Corporation reaffirmed a “buy” rating on shares of Celgene Corporation in a report on Wednesday. Cowen and Company reaffirmed a “buy” rating and set a $150.00 price objective on shares of Celgene Corporation in a report on Tuesday. Vetr downgraded shares of Celgene Corporation from a “buy” rating to a “hold” rating and set a $145.17 price objective for the company. in a report on Wednesday, September 6th. BTIG Research reaffirmed a “neutral” rating on shares of Celgene Corporation in a report on Tuesday, September 5th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Celgene Corporation in a report on Monday, August 28th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $147.31.

Shares of Celgene Corporation (NASDAQ CELG) traded down 0.50% during midday trading on Thursday, hitting $140.55. 3,074,739 shares of the company were exchanged. The stock has a market cap of $109.96 billion, a PE ratio of 43.53 and a beta of 1.89. The stock’s 50-day moving average is $134.74 and its 200-day moving average is $127.31. Celgene Corporation has a one year low of $96.93 and a one year high of $142.64.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. The company had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s revenue for the quarter was up 18.7% compared to the same quarter last year. During the same period last year, the firm earned $1.44 EPS. Equities research analysts anticipate that Celgene Corporation will post $7.32 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Royal Bank Of Canada Initiates Coverage on Celgene Corporation (CELG)” was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/09/14/royal-bank-of-canada-initiates-coverage-on-celgene-corporation-celg.html.

In related news, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the transaction, the director now directly owns 85,551 shares in the company, valued at $12,110,599.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Robert J. Hugin sold 175,970 shares of the company’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the completion of the transaction, the insider now owns 1,033,909 shares in the company, valued at $138,688,553.26. The disclosure for this sale can be found here. Insiders sold 267,476 shares of company stock worth $35,812,841 over the last 90 days. 0.95% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the stock. Capital Counsel LLC NY lifted its position in Celgene Corporation by 0.4% during the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 6 shares during the period. Fort Pitt Capital Group LLC lifted its position in Celgene Corporation by 0.6% during the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 11 shares during the period. Sowell Financial Services LLC lifted its position in Celgene Corporation by 0.5% during the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 13 shares during the period. South Texas Money Management Ltd. lifted its position in Celgene Corporation by 0.6% during the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 15 shares during the period. Finally, Flagship Harbor Advisors LLC lifted its position in Celgene Corporation by 0.9% during the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after purchasing an additional 18 shares during the period. Institutional investors and hedge funds own 79.43% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

The Fly

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.